Donghan Luo

568 total citations
38 papers, 424 citations indexed

About

Donghan Luo is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Donghan Luo has authored 38 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hepatology, 16 papers in Infectious Diseases and 16 papers in Epidemiology. Recurrent topics in Donghan Luo's work include Hepatitis C virus research (18 papers), HIV/AIDS drug development and treatment (16 papers) and Liver Disease Diagnosis and Treatment (11 papers). Donghan Luo is often cited by papers focused on Hepatitis C virus research (18 papers), HIV/AIDS drug development and treatment (16 papers) and Liver Disease Diagnosis and Treatment (11 papers). Donghan Luo collaborates with scholars based in United States, Belgium and Germany. Donghan Luo's co-authors include Gastón Picchio, Sandra De Meyer, Maria Beumont, Joost P.H. Drenth, Patrick Marcellin, Xavier Forns, Frederik Nevens, Tobias Goeser, Giampiero Carosi and Lawrence Serfaty and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Gastroenterology.

In The Last Decade

Donghan Luo

37 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donghan Luo United States	11	277	256	177	67	26	38	424
Laura Benítez‐Gutiérrez Spain	13	310 1.1×	278 1.1×	148 0.8×	49 0.7×	21 0.8×	20	414
Inmaculada Jiménez-Nàcher Spain	9	265 1.0×	235 0.9×	246 1.4×	86 1.3×	19 0.7×	19	471
Alain Landau France	9	314 1.1×	295 1.2×	163 0.9×	39 0.6×	13 0.5×	14	436
P. Wantzin Denmark	13	537 1.9×	513 2.0×	98 0.6×	21 0.3×	32 1.2×	26	671
D. Hueppe Germany	14	623 2.2×	562 2.2×	144 0.8×	10 0.1×	61 2.3×	47	673
Mark S. Sulkowski United States	7	383 1.4×	344 1.3×	81 0.5×	13 0.2×	21 0.8×	14	432
Aldo Trylesinski France	15	560 2.0×	696 2.7×	309 1.7×	190 2.8×	10 0.4×	44	926
L. Martín‐Herrera Spain	9	427 1.5×	378 1.5×	85 0.5×	17 0.3×	12 0.5×	11	573
G.B. Gaeta Italy	14	355 1.3×	329 1.3×	46 0.3×	12 0.2×	55 2.1×	44	505
María Sales Gilabert Spain	2	534 1.9×	476 1.9×	189 1.1×	46 0.7×	9 0.3×	5	624

Countries citing papers authored by Donghan Luo

Since Specialization

Citations

This map shows the geographic impact of Donghan Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donghan Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donghan Luo more than expected).

Fields of papers citing papers by Donghan Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donghan Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donghan Luo. The network helps show where Donghan Luo may publish in the future.

Co-authorship network of co-authors of Donghan Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Donghan Luo. A scholar is included among the top collaborators of Donghan Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donghan Luo. Donghan Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Shan, Donghan Luo, Gong Zhang, & Qingyuan Zhan. (2024). Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database. Frontiers in Medicine. 11. 1449194–1449194. 2 indexed citations

Baugh, Bryan, et al.. (2022). Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD. Journal of the International Association of Providers of AIDS Care (JIAPAC). 21. 2146006474–2146006474. 1 indexed citations

Lawitz, Eric, Fred Poordad, Julio Gutiérrez, et al.. (2020). Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study. Health Science Reports. 3(2). e145–e145. 5 indexed citations

Lathouwers, Erkki, et al.. (2020). Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection. SHILAP Revista de lepidopterología. 21(2-3). 83–89. 4 indexed citations

Huhn, Gregory, Joseph J. Eron, Pierre‐Marie Girard, et al.. (2019). Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study. AIDS Research and Therapy. 16(1). 23–23. 6 indexed citations

Huhn, Gregory, et al.. (2019). 887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) with the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial. Open Forum Infectious Diseases. 6(Supplement_2). S21–S21. 1 indexed citations

Opsomer, Magda, Dessislava I. Dimitrova, Simon Vanveggel, et al.. (2018). Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir. Drugs in R&D. 18(3). 199–210. 9 indexed citations

Bourgeois, Stefan, Yves Horsmans, Frederik Nevens, et al.. (2017). Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen. Antimicrobial Agents and Chemotherapy. 61(12). 6 indexed citations

Bourgeois, Stefan, Hans Van Vlierberghe, Christophe Moreno, et al.. (2017). Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. BMC Gastroenterology. 17(1). 26–26. 4 indexed citations

10.

Berg, Thomas, Pietro Andreoné, Stanislas Pol, et al.. (2014). Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study. Liver International. 35(2). 448–454. 5 indexed citations

11.

Picchio, Gastón, Sandra De Meyer, Inge Dierynck, et al.. (2014). Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection. Journal of Clinical Virology. 59(3). 148–155. 1 indexed citations

12.

Meyer, Sandra De, Anne Ghys, Inge Dierynck, et al.. (2014). Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. Virology Journal. 11(1). 93–93. 4 indexed citations

13.

Sarrazin, C., H.W. Reesink, Stefan Zeuzem, et al.. (2013). 898 TREATMENT WITH TELAPREVIR/PEG-IFN/RBV AFTER 14-DAY TELAPREVIR EXPOSURE IN PHASE I STUDIES: RESULTS FROM THE PHASE IIIB C219 ROLLOVER STUDY. Journal of Hepatology. 58. S369–S370. 3 indexed citations

14.

Benhamou, Y., J. Moussalli, Vlad Ratziu, et al.. (2013). Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial. The Journal of Infectious Diseases. 208(6). 1000–1007. 20 indexed citations

15.

Buti, Marı́a, Kosh Agarwal, Yves Horsmans, et al.. (2013). Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C. Gastroenterology. 146(3). 744–753.e3. 38 indexed citations

16.

Marcellin, Patrick, Xavier Forns, Tobias Goeser, et al.. (2010). Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C. Gastroenterology. 140(2). 459–468.e1. 114 indexed citations

17.

Glaspy, John A., Veena Charu, Donghan Luo, et al.. (2009). Initiation of epoetin‐α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy. Cancer. 115(5). 1121–1131. 7 indexed citations

18.

Orlowski, Robert Z., Heather J. Sutherland, Joan Bladé, et al.. (2007). Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.. Blood. 110(11). 2735–2735. 3 indexed citations

19.

Luo, Donghan & Thomas H. MacGregor. (1998). Multipliers of Fractional Cauchy Transforms and Smoothness Conditions. Canadian Journal of Mathematics. 50(3). 595–604. 5 indexed citations

20.

Connelly, Janet E., et al.. (1997). A Systematic Review and Meta‐analysis of the Incidence of Cancer in Randomized, Controlled Trials of Verapamil. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(6). 1210–1219. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact